foxo4-dri senolytic human trial 2024 Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment The disordered p53 transactivation domain
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications Focus on senescence: Clinical significance and practical applications Boccardi 2024 Journal of Internal Medicine Wiley Online Library GET RID OF ZOMBIE CELLS WITH FOXO4 DRI FOXO4 DRI is like a tiny tool scientists made to get rid of old, worn out cells in your body called senescent cells. These cells stop growing Peptide inhibitors targeting FOXO4 p53 interactions and inducing senescent cancer cell specific apoptosis bioRxiv
Pay in 4 interest-free payments of $7.06 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14


